Objective：To explore the clinical characteristics, pathology, prognosis and proper treatment of medullary carcinoma of the breast（MBC）. Methods：Retrospective analysis was carried out on the clinical data of 28 patients with MBC who admitted to our hospital from January 2004 to December 2010. Results：The incidence of MBC accounted for 2.9% of the breast cancer patients admitted to our hospital during the same period. The mean age was（50.68±12.63）years. The tumor size was 1-5 cm and axillary lymph node involvement was 47.6%. The overexpression of estrogen receptor（ER）, progesterone receptor（PR）, HER-2 / neu and p53 was 35.7%, 32%, 32%and 67.9%, respectively. All patients underwent operation and polychemotherapy（cyclophosphamide +Adriamycin, Paclitaxel+Adriamycin）; endocrine therapy was applied in five patients, and three cases received postoperative irradiation. All the patients were followed up from 1 month to 6 years, and the overall survival rate was 100%. Conclusions：MBC is an invasiveless histological type of breast carcinoma with good prognosis. Proper surgical and adjuvant therapy is important to improve the survival and quality of life. Attension should be paid to investigation of MBC associated antigens to provide new ideas for its treatment.